Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242138 | 0.78 | CYP1A2 (0.41) | CYP1A2FERMT2HTR1AADRA1DADRA1A | |
| SCHEMBL1742858 | 0.78 | MAPT (0.39) | BACE1NR4A2KMT2ACYP1A2RAB9A | |
| SCHEMBL1742856 | 0.78 | MAPT (0.39) | BACE1NR4A2KMT2ACYP1A2RAB9A | |
| SCHEMBL14031588 | 0.74 | TLR8 (0.50) | NR4A2FERMT2KDM4CRAB9ASMN1; SMN2 | |
| SCHEMBL3448086 | 0.73 | AOC1 (0.38) | CYP1A2FERMT2KDM4CRAB9AALDH1A1 | |
| SCHEMBL8666897 | 0.71 | BACE1 (0.55) | BACE1KMT2ACYP1A2KDM4CALDH1A1 | |
| SCHEMBL30482461 | 0.71 | BACE1 (0.33) | BACE1NR4A2KMT2AHRH4KDM4C | |
| SCHEMBL30148167 | 0.71 | CCR1 (0.38) | NR4A2CYP1A2FERMT2HTR1AADRA1D | |
| SCHEMBL4005235 | 0.71 | CCR1 (0.38) | NR4A2CYP1A2FERMT2HTR1AADRA1D | |
| SCHEMBL3909900 | 0.70 | ALDH1A1 (0.47) | CYP1A2HRH4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9630965-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-8586605-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069324-B1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2387316-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | Curis, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184801-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | CURIS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010083403-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | CURIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-2069324-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | Curis, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010152-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20170267674-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20100184801-A1 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS | IDH2, IDH1, AADAT | BACE1 2892/4885NR4A2 1753/4885KMT2A 811/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
| US-10035797-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | BACE1 4377/4885NR4A2 1765/4885KMT2A 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.